OGN — Organon & Co.
—
NYSE ·
Health Care ·
Pharmaceuticals ·
CIK 1821825 ·
Last close
$13.90
Market Cap
$3.65B
52W High
$13.91
52W Low
$5.67
ADV30
2,622,918
Next earnings
2026-10-30
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 1,574,000,000 | 869,000,000 | 365,000,000 | 164,000,000 | 13,401,000,000 | 1,455,000,000 | 12,208,000,000 |
| Jun 2026 | 1,558,000,000 | 847,000,000 | 323,000,000 | 108,000,000 | 13,178,000,000 | 1,132,000,000 | 12,172,000,000 |
| Mar 2026 | 1,460,000,000 | 783,000,000 | 266,000,000 | 146,000,000 | 12,996,000,000 | 1,116,000,000 | 12,093,000,000 |
| Dec 2025 | 1,507,000,000 | 741,000,000 | 217,000,000 | -205,000,000 | 12,867,000,000 | 574,000,000 | 12,115,000,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$737,000,000
Investing CF
$130,000,000
Financing CF
$-313,000,000
CapEx
$-303,000,000
Dividends Paid
$-18,000,000
Buybacks
—
EPS Diluted TTM
$0.77
As of
2026-11-01
Balance + Analyst (yfinance extras)
Retained Earnings
$1,352,000,000
Inventory
$1,351,000,000
Receivables
$1,492,000,000
ST Investments
—
EBIT TTM
$959,000,000
Pretax Income TTM
$491,000,000
Interest Exp TTM
$468,000,000
Analysts
3
Yahoo Snapshot (yfinance, live)
Total Revenue
$6,098,999,808
EBITDA
$1,582,000,000
Free Cash Flow
$747,000,000
Enterprise Value
$10,733,682,688
Total Cash
$1,455,000,064
Total Debt
$8,553,999,872
Shares Out
262,621,584
Trailing EPS
$0.78
Book Value
$4.54
ROE
20.3%
ROA
5.7%
Div Yield
0.58%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 6,216,000,000 | 1,226,000,000 | 187,000,000 | 12,867,000,000 | 12,115,000,000 | 752,000,000 | 700,000,000 |
| Dec 2024 | 6,403,000,000 | 1,486,000,000 | 864,000,000 | 13,101,000,000 | 12,629,000,000 | 472,000,000 | 939,000,000 |
| Dec 2023 | 6,263,000,000 | 1,327,000,000 | 1,023,000,000 | 12,058,000,000 | 12,128,000,000 | -70,000,000 | 799,000,000 |
| Dec 2022 | 6,174,000,000 | 1,705,000,000 | 917,000,000 | 10,955,000,000 | 11,847,000,000 | -892,000,000 | 858,000,000 |
TTM Snapshot
Revenues TTM
$6,127,000,000
NetIncome TTM
$209,000,000
OpCashFlow TTM
—
Assets (Latest)
$13,178,000,000
Forward EPS
$3.65
Max Pain — expiry 2027-01-15
max pain strike: $10.00 · spot: $13.92 · call oi: 1,495 · put oi: 8,184Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ABCL | AbCellera Biologics Inc. | $3.60B | $11.03 | — |
| TNGX | Tango Therapeutics, Inc. | $3.75B | $22.11 | — |
| AMLX | Amylyx Pharmaceuticals, Inc. | $3.54B | $27.52 | — |
| XENE | Xenon Pharmaceuticals Inc. | $3.81B | $38.78 | — |
| PBLS | Parabilis Medicines, Inc. | $3.49B | $28.25 | — |
News headlines (Yahoo Finance, 1h cache)
Organon Presents New Analysis of Pooled Post-Hoc Phase 3 Data on VTAMA® (tapinarof) cream, 1%, Demonstrating Consistent Efficacy in Atopic Dermatitis Across Diverse Patient Subgroups at ACAAI
2026-11-12 15:00 · Yahoo
Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know
2026-11-10 13:00 · Yahoo
New Real-World Evidence Presented by Organon at the American College of Rheumatology (ACR) Annual Meeting Evaluated a Large-Scale Switch to HADLIMA® (adalimumab-bwwd) Across United States Veterans Aff
2026-11-07 15:00 · Yahoo
Organon to Present New Analysis on VTAMA® (tapinarof) cream, 1% at the 2026 American College of Allergy, Asthma & Immunology Annual Scientific Meeting
2026-11-05 13:00 · Yahoo
Organon (OGN) Q3 Results Highlight A Thin Margin Cushion
2026-11-01 05:10 · Yahoo
Organon (OGN) Q3 Earnings and Revenues Top Estimates
2026-10-30 12:30 · Yahoo
Organon: Q3 Earnings Snapshot
2026-10-30 12:26 · Yahoo
Entera Appoints Global Research and Development Leader Dr. Juan Camilo Arjona Ferreira to Its Board of Directors
2026-10-27 12:00 · Yahoo
Organon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on It
2026-10-26 12:00 · Yahoo
Organon to Report Third Quarter 2026 Results in Its Regularly Scheduled Form 10-Q Filing
2026-10-19 11:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.